Novo Nordisk A/S (LON:0QIU)

Market Cap	160.83B
Revenue (ttm)	36.88B
Net Income (ttm)	12.13B
Shares Out	n/a
EPS (ttm)	2.73
PE Ratio	13.26
Forward PE	12.51
Dividend	1.32 (0.43%)
Ex-Dividend Date	Aug 15, 2025

Volume	2,158,809
Average Volume	1,330,631
Open	304.63
Previous Close	303.95
Day's Range	299.40 - 307.65
52-Week Range	267.05 - 800.00
Beta	0.24
RSI	47.73
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QIU

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK